The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

@article{ElGalaly2017TheNO,
  title={The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.},
  author={Tarec Christoffer El-Galaly and Diego Villa and Thomas Yssing Michaelsen and Martin Hutchings and Nabegh George Mikhaeel and Kerry J. Savage and Laurie H. Sehn and Sally F Barrington and Jakob Werner Hansen and Daniel Smith and Kirsty Rady and Karen Juul Mylam and Thomas Stauffer Larsen and Staffan Holmberg and Maja Bech Juul and Sabrina Cordua and Michael Roost Clausen and Kristina Bech Jensen and Hans Erik Johnsen and John F Seymour and Joseph M. Connors and Peter de Nully Brown and Martin B\ogsted and Chan Yoon Cheah},
  journal={European journal of cancer},
  year={2017},
  volume={75},
  pages={195-203}
}
PURPOSE Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International Prognostic Index (CNS-IPI) has been proposed for identifying patients at greatest risk, but the optimal model is unknown. METHODS We retrospectively analysed patients with diffuse large B-cell lymphoma diagnosed between 2001 and 2013, staged with PET/CT and treated with R-CHOP(-like) regimens. Baseline… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS
2 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…